• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Sandoz Site Directory
Sandoz : A Novartis Division
  • Our Work
    • What We Do
    • Quality Generics
    • Biopharmaceuticals
    • Specialty Products
    • Consumer Products
  • About Us
    • Who We Are
    • Corporate Responsibility
    • Doing Business Responsibly
    • Contact Us
    • Grants, Donations and Sponsorships
  • Products
    • Consumers
    • Patients
    • Healthcare Professionals
    • Patient Support Programs
  • News
    • Media Releases
    • Media Resource Center
    • Stay Up-To-Date
  • Careers
    • Available Positions
    • Our Benefits
    • Employee Testimonials
    • Our Values and Vision
    • Diversity & Inclusion
Search

Global Impact

  • Medicines
  • Discovery
  • Hope
  • Global Impact
  • Education & Awareness

Global Impact

Subscribe

Alberta’s biosimilars policy: another significant step towards improving patient access to safe, effective, and high-quality medicines in Canada

Globe

Global Sandoz Press Release about biosimilar Erelzi®

Important update about the Boucherville plant and development center

Recall of Ranitidine medicines

Announcement about Avara

Important update about the Boucherville plant and development center acquired by Avara

Important Announcement: Avara has acquired our plant and development center in Boucherville

Recall of Valsartan

Important Announcement

Sandoz Canada was recently featured in the Montreal Gazette

Sandoz Canada

  • Our Work
  • About Us
  • Products
  • News
  • Careers
  • Contact Us
  • Office Locations
  • Stay up to date

Subscribe to Sandoz

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • RSS
  • Sandoz Site Directory
© 2019 Sandoz AG

This site is intended for an audience in Canada

  • Terms of Use
  • Privacy Policy
  • Terms of Trade
  • Return Policy